Delving into the Latest Updates on Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd with Synapse

概览

关联

1

项与 Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd 相关的药物

RD-01

靶点

EPO receptor

作用机制

EPO receptor激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

2

项与 Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd 相关的临床试验

NCT04231292

/ Unknown status临床2期

A Multicenter, Randomized, Single-blind, Active Comparator Controlled Phase 2 Clinical Study on the Effectiveness, Safety and Pharmacokinetics of Pegerythropoietin Injection (RD01) in Different Medication Schemes for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

A multicenter randomized, single blind, active comparator controlled phase 2 study which is to evaluate the effectiveness, safety and the PK/PD characteristics of different doses, frequencies and routes of pegerythropoietin Injection (RD01) as maintenance therapy in the treatment of anemia in chronic renal failure patients with hemodialysis

开始日期2020-03-01

申办/合作机构

Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

NCT03657238

/ Completed临床1期

A Phase 1, Randomised, Double-blind, Single-centre, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single S.C. Doses of RD01 (Pegerythropoietin) in Healthy Chinese Subjects

A first-time in human study to investigate the safety, tolerability and pharmacokinetics of RD01 in healthy Chinese subjects

开始日期2018-04-08

申办/合作机构

Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

100 项与 Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd 相关的临床结果

登录后查看更多信息

0 项与 Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd 相关的专利（医药）

登录后查看更多信息

100 项与 Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd 相关的药物交易

登录后查看更多信息

100 项与 Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd 相关的转化医学

登录后查看更多信息